focus -WSS

focus

author：leisure time 2025-09-06 01:41:30 - browse：2

A sign of Lilly on the top of its biotechnology center — coverage from STAT — Adobe

Eli Lilly reported Thursday that its experimental weekly insulin worked as well as daily basal insulin products in two late-stage studies, paving the way for the drug to compete with a similar weekly insulin developed by Novo Nordisk.

In a 52-week trial of type 2 diabetes patients using insulin for the first time, those on the weekly insulin, called efsitora alfa, had a 1.34% reduction in blood sugar levels, while people on the comparator daily insulin degludec, sold as Tresiba by Novo, had a 1.26% lowering. That resulted in patients having blood sugar levels, known as A1C readings, of 6.87% and 6.95%, respectively.

In a separate 26-week trial of type 2 patients who have been using insulin, those on efsitora and the comparator daily insulin glargine, sold by Lilly as Basaglar and Sanofi as Lantus, both saw A1C reductions of 1.07%, resulting in blood sugar levels of 7.12% and 7.11%, respectively.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Medicare Advantage 2025 payments will dip, Biden administration says

leisure time

WSS

More people are opting for early dinners since the pandemic, says OpenTable CEO Debby Soo

Appeals court upholds Josh Duggar's conviction for downloading child sex abuse images

Drug companies' payments and gifts affect physicians' prescribing

Republican states more likely to report Covid vaccine side effects

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

The UK government moves asylum

leisure time

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

23andMe had bad news about my health. I wish a person had delivered it

DeSantis and Newsom agree to Sean Hannity debate, then disagree on the rules

United colonoscopy coverage change 'may cost lives,' doctors say

Why workplace violence is so common in health care

State Dept. review finds Biden bears some blame for Afghanistan failures

Teen said 'homophobic slurs' before O'Shae Sibley killing: Criminal complaint

Tori Bowie and the unacceptable rates of Black maternal death

Alzheimer's risk factor APOE4 may be a distinct form of the disease

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Oral obesity drug from Viking Therapeutics hits key early target

Wikipedia

Florida Supreme Court upholds state's abortion ban

Researchers test human milk's ability to repair gut microbiome

Insurer loopholes limit power of law against surprise medical bills

Boeing's 1st astronaut flight bumped into next year, more repairs needed

Thousands of Marines and sailors deploy to Middle East to deter Iran from seizing ships

Arizona Democrat to raise extreme heat with Biden 1 year out from Senate primary

leisure time

hotspot

entertainment

focus